All In Biotech

Drug Trial Radar · NCT05387603

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An Open-label, Multicenter, Randomized Phase III Trial Comparing Safety and Efficacy of Personalized Versus Non-personalized Radionuclide Therapy With 177Lu (Lutetium)-DOTATOC.

Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Oct 1, 2026

Study completion Oct 1, 2026

Sponsor

Lead sponsor
Lund University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.

Conditions

  • Neuroendocrine Tumors

Interventions

  • 177Lu-DOTATOCDrug

    The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor). The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing.

  • CapecitabineDrug

    Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median progression free survival (PFS) defined as time from randomization to radiological progression.Time frame: Before start of treatment (within 4 weeks), then every 10 +/- 2 weeks weeks, at follow up (every 3-6 month (investigators choice) until progression.
  2. Median progression free survival (PFS) defined as time from randomization to radiological progression.Time frame: Before start of treatment (within 4 weeks), then every 10 +/- week at follow up (every 3-6 month (investigators choice) until death.
  3. Median progression free survival (PFS) defined as time from randomization to radiological progression,Time frame: Before start of treatment (within 4 weeks), then every 10 +/- 2 weeks, at follow up (every 3-6 month (investigators choice) or patients withdrawal of concent.. No end can be given.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Sahlgrenska University Hospital, Dept. of Oncology

    Gothenburg, Sweden · Recruiting

  • Skåne University Hospital, Dept. of Oncology

    Lund, Sweden · Recruiting

  • Karolinska University Hospital, Dept. of Oncology

    Stockholm, Sweden · Recruiting

  • Accademical Hospital, Uppsala, Dept. of Oncology

    Uppsala, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.